Abstract
Introduction
The rapid increase in prescribing and use of opioids for chronic noncancer pain has coincided with an increase in opioid-related harms. 1, 2 Tapentadol (Palexia, Grunenthal, Germany) and controlled release oxycodone/naloxone (Targin, Mundipharma, UK) are two recently marketed opioid analgesics in Australia. 3, 4 The number of tapentadol dispensings subsidized by the Pharmaceutical Benefits Scheme (PBS) increased from over 55,000 in 2014 to over 250,000 in 2015. Oxycodone/naloxone PBS subsidized dispensings increased from over 200,000 in 2012 to over 1.7 million in 2015. 5 Although there has been considerable uptake in the use of these two opioids since registration, there are limited published data on postmarketing adverse drug events (ADEs). Tapentadol and oxycodone/naloxone are reimbursed through Australia's PBS for the management of chronic severe disabling pain unresponsive to nonopioid analgesics. 6 Tapentadol, a centrally acting μ-opioid receptor agonist and noradrenaline reuptake inhibitor, [7] [8] [9] was first approved for marketing by the Therapeutic Goods Administration (TGA) in 2011. Oxycodone/naloxone was first marketed in Australia in 2010. Combining oxycodone with naloxone, a peripherally acting μ-opioid receptor antagonist, was designed to reduce the incidence of opioid-induced constipation. 10, 11 The most recent Australian Public Assessment Report (AusPAR) for tapentadol highlights the potential for serotonin syndrome. 4 We are aware of three previous case reports of serotonin syndrome with tapentadol, although all three cases involved coadministration of tapentadol with other serotonergic agents including venlafaxine, duloxetine and amitriptyline. [12] [13] [14] A systematic review of four randomized controlled trials conducted over a 3-to 12-week period suggested the addition of naloxone to oxycodone reduces the incidence of opioidinduced constipation without causing a reversal of analgesia. 15 However, in order for naloxone to undergo first pass metabolism and avoid the systemic circulation, normal hepatic function is required. 16, 17 For this reason, recent clinical practice guidelines suggest avoiding oxycodone/naloxone in people with hepatic impairment as it may reduce analgesia or lead to opioid withdrawal in people who are opioid tolerant. 18, 19 There are a limited number of published studies on ADEs related to tapentadol and controlled release oxycodone/naloxone. A recent systematic review comparing tapentadol and oxycodone/ naloxone showed that the most commonly reported ADEs for both medications were dizziness, headache and fatigue. 20 Furthermore, ADEs involving the gastrointestinal tract (nausea, vomiting and constipation) were reported for both opioids at similar rates to those reported in premarketing trials and AusPAR. 3, 4, 9, 20, 21 However, less common and rare adverse events are often identified by postmarketing surveillance data. The ADE profile of tapentadol and oxycodone/naloxone may be different in routine practice than in the clinical trials because people prescribed these medications in routine practice may have different characteristics to the clinical trial participants. In Australia, there are currently no published studies of spontaneous ADE reports linked to these two newly marketed opioids. Therefore, the objective of this study was to describe spontaneous adverse event reports related to tapentadol and oxycodone/naloxone in Australia. We compared spontaneously reported ADEs with those reported in the literature, and focused on ADEs not confirmed or well established in previous literature. 
Methodology

Data source
Data extraction
Information on each patient's age, sex, causality of the ADE, opioid used, type of reaction [using the MedDRA classification system], onset of reaction, reporter, concomitant medications (includes concomitant medications, tapentadol and oxycodone/naloxone) and outcome were extracted by two independent investigators. Any discrepancies were resolved with a third investigator. Duplicates were removed.
Data analysis
Data are described using means with standard deviations for continuous variables and proportions for categorical variables. MedDRA reaction terms were grouped according to the system organ class. For each opioid the four most commonly reported MedDRA system organ classes were identified.
Ethical review
The Monash University Human Research Ethics Committee deemed the study to be exempt from needing ethics approval.
Results
In total, 106 public case detail reports were retrieved for tapentadol between September 2013 and March 2017 and 250 cases for oxycodone/ naloxone between April 2011 and March 2017. Of these, three public case detail reports were duplicated for tapentadol and one case detail was a group summary case report for oxycodone/ naloxone. Therefore, the total number of public case detail reports for tapentadol were 104 and 249 for oxycodone/naloxone. Characteristics of public case detail reports for both opioids are reported in Table 1 . The mean age of patients with a reported ADE was 54.2 years for tapentadol and 62.8 years for oxycodone/naloxone. There were more ADE reports for women than men (69.4% tapentadol, 59.4% oxycodone/ naloxone). The most common reporter was the pharmaceutical company (47.2% tapentadol, 54.4% oxycodone/naloxone). The total mean number of medications used by patients was 2.67 for tapentadol and 3.57 for oxycodone/naloxone. Most patients in both groups were documented to have recovered from the ADE (tapentadol 87%, oxycodone/naloxone 76.4%).
The most prevalent ADEs for tapentadol were nervous system disorders (n = 52, 50%), psychiatric (n = 34, 32.7%), gastrointestinal (n = 18, 17.3%), and general disorders and administration site conditions (n = 21, 20.2%) ( Table 2) . Sixteen (23.2%) of 69 nervous system disorders reaction terms were consistent with serotonin syndrome, and of these, 14 (87.5%) patients were reported to be taking another serotonergic drug in conjunction with tapentadol. Concomitant medications implicated in serotonin syndrome included tramadol, duloxetine, venlafaxine, desvenlafaxine, amitriptyline, sertraline, and escitalopram. The two remaining cases where serotonin syndrome was reported did not have specific details regarding concomitant medication use or patient characteristics. The most common psychiatric disorders reported for tapentadol were delirium (n = 7, 18.4%), hallucination (n = 5, 13.1%), and confusional state (n = 5, 13.1%). For general disorders and administration site conditions the most frequent reports were malaise (n = 5, 20.8%) and drug was considered ineffective (n = 4, 16.6%). The most common gastrointestinal ADEs reported were nausea (n = 10, 41.6%), upper abdominal pain (n = 2, 8.3%), and vomiting (n = 2, 8.3%). Figure 1 displays the two most common reaction terms of the four most common MedDRA organ system class of tapentadol.
The most prevalent ADEs for oxycodone/naloxone were psychiatric disorders (n = 78, 31.3%), gastrointestinal (n = 73, 29.3%), general disorders and administration site conditions (n = 87, 35%), and nervous system (n = 62, 24.9%) ( Table  2 ). The most common psychiatric disorders reported were hallucination (n = 22, 17%), delirium (n = 12, 9.3%), and withdrawal syndrome (n = 12, 9.3%). The most frequently reported reaction terms for gastrointestinal disorders were nausea (n = 24, 20.7%) and diarrhoea (n = 23, 19.9%). For nervous system disorders the most commonly reported ADEs were dizziness (n = 9, 10.7%), somnolence (n = 8, 9.5%), and tremor (n = 8, 9.5%). The most frequently reported general disorders and administration site conditions were drug withdrawal syndrome (n = 28, 26%) and that the drug was considered ineffective (n = 9, 8.3%). Figure 2 displays the two most common reaction terms of the four most common MedDRA organ system class of oxycodone/naloxone. There were 28 (26%) public case details reporting the reaction of drug withdrawal syndrome related to oxycodone/naloxone use. Further, there were 12 (9.3%) cases reporting withdrawal syndrome. These two MedDRA reaction terms were used in 40 (16%) public case detail reports. Of these, 25 (62.5%) public case detail reports documented use of another opioid prior to the prescriber changing the therapy to oxycodone/naloxone. There were seven cases of injecting oxycodone/ naloxone that resulted in drug withdrawal syndrome/withdrawal syndrome with one of these public case details also documenting prior opioid use. The remaining nine public case detail reports did not have documentation of prior opioid use. Across the 249 reports we identified nine documented public case details suspecting or confirming degrees of hepatic impairment and raised liver enzymes. Four of these cases were implicated in reports of withdrawal reactions.
Discussion
Our study identified that serotonin syndrome was the most frequently reported ADE with tapentadol, and 'drug withdrawal syndrome' and 'withdrawal syndrome' collectively were the most frequently reported ADE for oxycodone/naloxone. These ADEs are less well known and described in previous literature than other reported ADEs in our study. Other reported ADEs in our study are similar to those reported in the product information (PI) for each opioid. The most recent PI for tapentadol lists dizziness, somnolence, headache, nausea and vomiting as the most commonly reported ADEs in clinical trials. 22 Oxycodone/ naloxone PI includes nausea, vomiting, headache, somnolence, constipation, hyperhidrosis, and fatigue as the most commonly reported ADEs. 23 ADEs related to oxycodone/naloxone were reported for people of higher average age than in tapentadol-related ADEs, while more ADEs were reported for women than men for both opioids.
The mean age of people reported with an ADE using tapentadol was 54 years and in people using oxycodone/naloxone was 63 years. This is somewhat consistent with the mean ages of participants in clinical trials. In tapentadol trials the mean age of participants was 62 years and the mean age of participants in oxycodone/naloxone trials was 56 years. 3, 4 The proportion of female sex was higher in both tapentadol and oxycodone/naloxone reports. This is consistent with the overall prescribing of opioids being higher in the female population. 24 Sixteen cases of serotonin syndrome related to tapentadol use were reported to the TGA. In 12 cases tapentadol was coadministered with one other serotonergic medication and in two cases with two other serotonergic medications. Additionally, there were two cases of serotonin syndrome in which there was no documented coadministration with other serotonergic medications. Three published case reports of suspected serotonin syndrome associated with tapentadol were published in prior literature. [12] [13] [14] In all three case reports tapentadol was coadministered with medications known to contribute to serotonin syndrome. [12] [13] [14] We are not aware of any published cases of serotonin syndrome in which tapentadol was the sole causative agent. 25 Interestingly, the most recent AusPAR for tapentadol published in February 2011 from the TGA indicates a theoretical risk of serotonin syndrome with other serotonergic medications, however a causal relationship has not been established. 4 Furthermore, the US Food and Drug Administration has issued warnings about the risk of serotonin syndrome when tapentadol is used with other serotonergic medication. 26 Tapentadol has been shown to have two mechanisms of action through the μ-opioid receptor and also has activity on noradrenaline receptors inhibiting reuptake of noradrenaline. 7, 27 Current literature suggests tapentadol has minimal effects on serotonin reuptake inhibition. 27, 28 Although it has been reported that tapentadol has minimal activity on serotonin receptors, our study highlights the possibility that tapentadol may contribute to serotonin syndrome when used alone or concomitantly with other serotonergic agents. However, further investigation is needed to determine whether tapentadol can cause serotonin syndrome as the sole causative agent.
There were 40 public case detail reports in total with the MedDRA reaction terms 'drug withdrawal syndrome' and 'withdrawal syndrome' for oxycodone/naloxone. In clinical trials there was a low incidence of drug withdrawal symptoms when patients were switched from other opioids to oxycodone/naloxone. Our study highlights the possibility of drug withdrawal syndromes when patients are switched from other opioids. We identified 25 withdrawal reactions resulting from a switch from other opioids to oxycodone/naloxone. The PI for Targin states that patients undergoing long-term opioid therapy may initially experience withdrawal symptoms if the prescriber changes therapy to oxycodone/naloxone. 23, 29 Of the 40 public case detail reports who had a withdrawal reaction we identified four cases of hepatic impairment and or raised liver enzymes. This is consistent with the literature which has reported cases of drug withdrawal with oxycodone/naloxone when used in patients with hepatic impairment. 16, 17, 30 Liver problems can result in lowered first pass metabolism of naloxone, making it more systemically bioavailable thus precipitating withdrawal symptoms. 16, 17 The PI for Targin states that oxycodone/naloxone should be used with caution in patients with mild hepatic impairment and is contraindicated in patients with moderate to severe hepatic impairment. 23 Patients with hepatic impairment may be more likely to experience withdrawal syndrome and therefore clinicians should exercise care and monitor patients when prescribing oxycodone/naloxone in hepatic impairment. 19 There were seven cases of injecting oxycodone/naloxone that resulted in drug withdrawal syndrome/withdrawal syndrome. There are previous reports of withdrawal symptoms arising from misuse of oxycodone/naloxone formulations. 17 Intravenously injecting oxycodone/naloxone results in the naloxone component acting on opioid receptors in the peripheral and central nervous systems precipitating drug withdrawal in opioid-tolerant people. 17
Strengths and limitations
The strength of our study is that we included all adverse event reports in Australia for tapentadol and oxycodone/naloxone recorded up until March 2017. Spontaneous adverse event reporting is voluntary for patients and health care professionals whereas it is mandatory for pharmaceutical companies. Health care professionals may have been more likely to report serious rather than nonserious adverse events. This means that ADEs reported are unlikely to be representative of all potential ADEs that occur in clinical practice. As with other analyses of spontaneous ADE reports, it was not possible to estimate the incidence of ADEs associated with tapentadol and oxycodone/ naloxone. Additionally, ADE reporting may have incomplete reporting/documentation of concomitant medications. This means that serotonin syndrome reported due to tapentadol use as a sole agent cannot be confirmed. Further, withdrawal reactions occurring when oxycodone/naloxone is used without switching from prior opioids cannot be confirmed due to the potential of incomplete reporting. Additional follow-up information for these cases was not available. Information such as time to onset of reaction, rechallenge data and duration of treatment were not available for most cases so we were not able to report these data.
Conclusion
Our study emphasizes the need for routine monitoring of ADEs for people using tapentadol or oxycodone/naloxone. Our study highlights the need for caution and ongoing monitoring when prescribing tapentadol in patients already taking serotoninergic medications. Clinicians should also exercise caution when switching from another opioid to oxycodone/naloxone or when prescribing oxycodone/naloxone to patients with hepatic impairment. This is important to avoid drug withdrawal syndrome and reduced analgesia. 
